Aikedakan Particles Produce Effect On CD4,CD8 Of The Medium-Term Primary Liver Cancer Patients

Objective: the medium-term outlook Cha yikedakang tablets treatment of primary liver cancer CD4~+,CD8~+activity, aimed at the Chinese medicine treatment of primary liver cancer to further investigate the mechanism for the Integrated Treatment of primary liver cancer looking for the medium-term theory.Methods: 60 patients with medium-term treatment of primary liver cancer were randomly divided into 30 cases and the control group 30. Both groups were given symptomatic treatment and Liver conventional treatment group in this basis, taking Yikedakang particles, with a course of 2 months. Were clinical symptoms were observed before and after treatment to improve the situation, CD4~+,CD8~+ activity and CD4~+/CD8~+ratio, liver function, AFP and other changes, compared with the control group to analyze the differences.Results:1. The treatment group before and after treatment CD4~+ concentration, P <0.05, significant difference, compared with control group P <0.05, significant difference.2. The treatment group before and after treatment CD4~+,CD8~+ ratio increased, P <0.05, significant difference, compared with control group P <0.05, two groups were significantly different.3. The treatment group before and after treatment decreased CD8~+levels, P> 0.05, the difference was not statistically significant compared with control group P> 0.05, two groups were not significantly different.4. The treatment group improved liver function and reduce the AFP so better than the control group.5. Karnofsky score: the treatment group improved significantly higher steady rate, P <0.05, statistically significant decline in the treatment group was lower than the control group, P <0.05, statistically significant.6. Comparison of body weight change : The treatment group improved significantly higher steady rate, P <0.05, statistically significant decline in the treatment group was lower than the control group, P <0.05, statistically significant.conclusions:1. yikedakang medium-term treatment of primary particles the exact onset of liver cancer, the treatment group than the control group.2. Through the system of clinical observation, yikedakang particles can increase the concentration of CD4~+ T lymphocytes and CD4~+/CD8~+ratio, indicating the drug increased the medium-term immunity in patients with primary liver cancer.3. yikedakang particles in the medium-term treatment of primary liver cancer patients can improve symptoms, improve liver function and quality of life, there is a genuine effect.